These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 26457416

  • 1. Treatment Options for Age-Related Macular Degeneration: A Budget Impact Analysis from the Perspective of the Brazilian Public Health System.
    Elias FT, Silva EN, Belfort R, Silva MT, Atallah ÁN.
    PLoS One; 2015; 10(10):e0139556. PubMed ID: 26457416
    [Abstract] [Full Text] [Related]

  • 2. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ, Mendes MA, Bounthavong M, Christopher ML, Boggie D, Morreale AP.
    J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
    [Abstract] [Full Text] [Related]

  • 3. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
    Neubauer AS, Holz FG, Schrader W, Back EI, Kühn T, Hirneiss C, Kampik A.
    Klin Monbl Augenheilkd; 2007 Sep; 224(9):727-32. PubMed ID: 17846963
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective.
    Nunes RP, Hirai FE, Rodrigues EB, Farah ME.
    Arq Bras Oftalmol; 2020 Sep; 83(1):48-54. PubMed ID: 32130306
    [Abstract] [Full Text] [Related]

  • 5. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness.
    Raftery J, Clegg A, Jones J, Tan SC, Lotery A.
    Br J Ophthalmol; 2007 Sep; 91(9):1244-6. PubMed ID: 17431015
    [Abstract] [Full Text] [Related]

  • 6. Model study of AREDS antioxidant supplementation of AMD compared to Visudyne: a dominant strategy?
    Trevithick J, Massel D, Robertson JM, Tomany S, Wall R.
    Ophthalmic Epidemiol; 2004 Dec; 11(5):337-46. PubMed ID: 15590581
    [Abstract] [Full Text] [Related]

  • 7. Cost effectiveness of treatments for wet age-related macular degeneration.
    Mitchell P, Annemans L, White R, Gallagher M, Thomas S.
    Pharmacoeconomics; 2011 Feb; 29(2):107-31. PubMed ID: 21244102
    [Abstract] [Full Text] [Related]

  • 8. [The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes].
    Karel I.
    Cesk Slov Oftalmol; 2007 Sep; 63(5):311-9. PubMed ID: 17915581
    [Abstract] [Full Text] [Related]

  • 9. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
    Campbell RJ, Bell CM, Paterson JM, Bronskill SE, Moineddin R, Whitehead M, Gill SS.
    Ophthalmology; 2012 Aug; 119(8):1604-8. PubMed ID: 22717458
    [Abstract] [Full Text] [Related]

  • 10. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
    Fletcher EC, Lade RJ, Adewoyin T, Chong NV.
    Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
    [Abstract] [Full Text] [Related]

  • 11. Economic implications of current age-related macular degeneration treatments.
    Smiddy WE.
    Ophthalmology; 2009 Mar; 116(3):481-7. PubMed ID: 19157562
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in Germany: Model analysis from the perspective of Germany's statutory health insurance system.
    Neubauer AS, Holz FG, Sauer S, Wasmuth T, Hirneiss C, Kampik A, Schrader W.
    Clin Ther; 2010 Jul; 32(7):1343-56. PubMed ID: 20678682
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The economic impact of blue-light filtering intraocular lenses on age-related macular degeneration associated with cataract surgery: a third-party payer's perspective.
    Reddy P, Gao X, Barnes R, Fairchild C, Boci K, Waycaster C, Pashos C.
    Curr Med Res Opin; 2006 Jul; 22(7):1311-8. PubMed ID: 16834830
    [Abstract] [Full Text] [Related]

  • 15. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial.
    Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, Daly MK, Houranieh A, Feinberg EB.
    Eye (Lond); 2010 Nov; 24(11):1708-15. PubMed ID: 20885427
    [Abstract] [Full Text] [Related]

  • 16. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
    Landa G, Amde W, Doshi V, Ali A, McGevna L, Gentile RC, Muldoon TO, Walsh JB, Rosen RB.
    Ophthalmologica; 2009 Nov; 223(6):370-5. PubMed ID: 19590252
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
    Abouammoh M, Sharma S.
    Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
    [Abstract] [Full Text] [Related]

  • 20. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.
    Stepien KE, Rosenfeld PJ, Puliafito CA, Feuer W, Shi W, Al-Attar L, Dubovy SR, Murray TG, Davis JL, Lee WH, Schwartz SG, Smiddy WE, Berrocal AM, Flynn HW.
    Retina; 2009 Sep; 29(8):1067-73. PubMed ID: 19696701
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.